Lymphoma cells lacking pro-apoptotic BAX are highly resistant to BH3-mimetics targeting pro-survival MCL-1 but retain sensitivity to conventional DNA-damaging drugs

BH3-mimetic drugs are an anti-cancer therapy that can induce apoptosis in malignant cells by directly binding and inhibiting pro-survival proteins of the BCL-2 family. The BH3-mimetic drug venetoclax, which targets BCL-2, has been approved for the treatment of chronic lymphocytic leukaemia and acute...

Descripción completa

Detalles Bibliográficos
Autores principales: Diepstraten, Sarah T., Young, Savannah, La Marca, John E., Wang, Zilu, Kluck, Ruth M., Strasser, Andreas, Kelly, Gemma L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070326/
https://www.ncbi.nlm.nih.gov/pubmed/36755070
http://dx.doi.org/10.1038/s41418-023-01117-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10070326/
https://www.ncbi.nlm.nih.gov/pubmed/36755070
http://dx.doi.org/10.1038/s41418-023-01117-0

Ejemplares similares